APRE (Aprea Therapeutics) Buyback Yield %: -403.74 (As of Jul. 01, 2026)


APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.72
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics Buyback Yield %?

Aprea Therapeutics APRE -7.07% 30 Buyback Yield % is -403.74 as of Jul. 01, 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 745 Biotechnology companies, Aprea Therapeutics ranks worse than 97.99% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aprea Therapeutics's current buyback yield was -403.74%.

Aprea Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Aprea Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics Buyback Yield % Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only -2.45 -3.89 -32.96 -89.51 -72.23

Aprea Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -4.72 -9.46 -72.23 -438.50

APRE vs JSPR, CVKD, BRTX: Buyback Yield % Comparison

For the Biotechnology subindustry, Aprea Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprea Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's Buyback Yield % falls into.


APRE
30GF Score
Aprea Therapeutics Inc APRE
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aprea Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 5.048) / 6.988629
=-72.23%

Aprea Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 40.087) / 9.1418307
=-438.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -403.74 mean?
Aprea Therapeutics (APRE) has a Buyback Yield % of -403.74 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Aprea Therapeutics and its competitors. According to the industry distribution chart, Aprea Therapeutics ranks #730 out of 745 companies in the Biotechnology industry, placing it in the top 98%.
Is Aprea Therapeutics' Buyback Yield % too high?
Aprea Therapeutics' current Buyback Yield % is -403.74. Based on the distribution chart, Aprea Therapeutics ranks #730 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' Buyback Yield % compare to JSPR and CVKD?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #730 out of 745 companies for Buyback Yield %. This places Aprea Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Aprea Therapeutics and its competitors. Aprea Therapeutics's current Buyback Yield % is -403.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current Buyback Yield % of -403.74. The current Buyback Yield % is -403.74. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current Buyback Yield % is -403.74 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price